2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof,

wherein:

X is O, S or CH 2 ;

A is C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, 5- or 6-membered monocyclic heteroaryl, —N(R 20 ) 2 , —S—(C 1 -C 6 alkyl), —S(O)—(C 1 -C 6 alkyl), —S(O) 2 —(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene)-OH, —(C 1 -C 6 alkylene)-N(R 20 ) 2 , —NHSO 2 —(C 1 -C 6 alkyl), —NHC(O)N(R 20 ) 2 , —NHOH, —C(O)OR 20 , —C(O)N(R 20 ) 2 , —NHC(O)R 20 or —NHC(O)OR 20 , or group A and the —OR 2 group of formula (I) can join to form —OC(O)—NH—;

B is selected from one of the following groups:

Y is N or —C(R 19 )—;

Z is N or —CH—;

R 1 is H,

R 2 is H, or R 1 and R 2 join to form a group having the formula:

R 3 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 7 cycloalkyl;

R 4 , R 5 , R 7 and R 8 are each independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, halo, —OR 20 , —SR 20 or —N(R 20 ) 2 ;

R 6 , R 9 , R 10 , R 11 are each independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, halo, —OR 20 , —SR 20 , —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —NHC(O)OR 20 , —NHC(O)N(R 20 ) 2 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 20 ) 2 , —NH(C 1 -C 6 alkylene)-(5- or 6-membered monocyclic heteroaryl), —NH(C 1 -C 6 alkylene)-(9- or 10-membered bicyclic heteroaryl), —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 and —NHC(O)R 20 , wherein said C 2 -C 6 alkenyl group and said C 2 -C 6 alkynyl group can be optionally substituted a halo group;

R 12 is H or —(C 1 -C 6 alkylene)-T-R 21 ;

R 13 is H or —(C 1 -C 6 alkylene)-T-R 21 , or R 12 and R 13 can join to form a C 2 -C 4 alkylene group between the oxygen atoms that R 12 and R 13 are attached to, wherein said C 2 -C 4 alkylene group is substituted with at least one C 6 -C 10 aryl group;

R 14 is H, C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein said C 6 -C 10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R 22 ;

R 15 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl or benzyl, wherein said C 1 -C 6 alkyl can be optionally substituted with a group selected from halo, —OR 20 , SR 20 , guanidino, —N(R 20 ) 2 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —NHC(O)R 20 , 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group can be optionally substituted with up to 2 groups, each independently selected from C 1 -C 6 alkyl, halo and —OR 20 ;

R 16 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl or benzyl, wherein said C 1 -C 6 alkyl can be optionally substituted with a group selected from halo, —OR 20 , —SR 20 , guanidino, —N(R 20 ) 2 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —NHC(O)R 20 , 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group can be optionally substituted with up to 2 groups, each independently selected from C 1 -C 6 alkyl, halo and —OR 20 ;

R 17 is H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, —(C 1 -C 3 alkylene) m -C 3 -C 7 cycloalkyl, —(C 1 -C 3 alkylene) m -C 6 -C 10 aryl or adamantyl, wherein said C 1 -C 20 alkyl group, said C 2 -C 20 alkenyl group, said C 6 -C 10 aryl group and said adamantyl group can be optionally substituted with up to three groups, each independently selected from halo, —OR 20 , —C(O)OR 20 , CN, NO 2 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 7 cycloalkyl, C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —N(R 20 ) 2 , —C(O)N(R 20 ) 2 —SR 20 , —S(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —NHC(O)R 20 , —NHC(O)OR 20 and —NHC(O)N(R 20 ) 2 and;

R 18 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, —(C 1 -C 3 alkylene) m -C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl or:

wherein said C 6 -C 10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five groups, each independently selected from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halo, —OR 20 , —SR 20 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 20 ) 2 , —C(O)OR 20 , —C(O)N(R 20 ) 2 and —NHC(O)R 20 ;

R 19 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, halo, —OR 20 , —SR 20 , N(R 20 ) 2 , C 3 -C 7 cycloalkyl, C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl or 9- or 10-membered bicyclic heteroaryl;

each occurrence of R 20 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —(C 1 -C 3 alkylene) m -(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl), —(C 1 -C 3 alkylene) m -(4 to 7-membered heterocycloalkyl), —(C 1 -C 3 alkylene) m -(5- or 6-membered monocyclic heteroaryl) or —(C 1 -C 3 alkylene) m -(9- or 10-membered bicyclic heteroaryl), wherein said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -(5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R 26 ;

each occurrence of R 21 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —OR 20 , —O—(C 1 -C 6 haloalkyl) or —N(R 20 ) 2 , wherein said C 2 -C 6 alkenyl group, said C 2 -C 6 alkynyl group, said C 3 -C 7 cycloalkyl group, said C 3 -C 7 cycloalkenyl group, said C 6 -C 10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five groups, each independently selected from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halo, —OR 20 , —SR 20 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 20 ) 2 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 and —NHC(O)R 20 ;

R 22 represents from one to five substituent groups, each independently selected from C 1 -C 6 alkyl, halo, —OR 20 , —SR 20 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 20 ) 2 , —C(O)OR 20 , —C(O)N(R 20 ) 2 and —NHC(O)R 20 , or any two R 22 groups on adjacent ring carbon atoms can combine to form —O—R 23 —O—;

R 23 is —[C(R 24 ) 2 ] n —;

each occurrence of R 24 is independently H or C 1 -C 6 alkyl;

each occurrence of R 25 is independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl), 4 to 7-membered heterocycloalkyl, 5- or 6-membered monocyclic heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein said C 1 -C 6 alkyl group, said C 2 -C 6 alkenyl group, said C 2 -C 6 alkynyl group, said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -(5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R 26 ; or two R 25 groups, together with the common nitrogen atom to which they are attached, join to form a 4- to 7-membered heterocycloalkyl group;

R 26 represents from one to five substituent groups, each independently selected from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halo, —OR 27 , —SR 27 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 27 ) 2 , —C(O)OR 27 , —C(O)N(R 27 ) 2 and —NHC(O)R 27 ;

each occurrence of R 27 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —(C 1 -C 3 alkylene) m -(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl), —(C 1 -C 3 alkylene) m -(4 to 7-membered heterocycloalkyl), —(C 1 -C 3 alkylene) m -(5- or 6-membered monocyclic heteroaryl) or —(C 1 -C 3 alkylene) m -(9- or 10-membered bicyclic heteroaryl);

R 28 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —OR 20 , —O—(C 1 -C 6 haloalkyl) or —N(R 20 ) 2 , wherein said C 2 -C 6 alkenyl group, said C 2 -C 6 alkynyl group, said C 3 -C 7 cycloalkyl group, said C 3 -C 7 cycloalkenyl group, said C 6 -C 10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five groups, each independently selected from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halo, —OR 20 , —SR 20 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 20 ) 2 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 and —NHC(O)R 20 ;

each occurrence of R 29 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —(C 1 -C 3 alkylene) m -(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl), —(C 1 -C 3 alkylene) m -(4 to 7-membered heterocycloalkyl), —(C 1 -C 3 alkylene) m -(5- or 6-membered monocyclic heteroaryl) or —(C 1 -C 3 alkylene) m -(9- or 10-membered bicyclic heteroaryl), wherein said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -(5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with R 26 ;

each occurrence of T is independently —S—, —O—, —SC(O)—, —SC(S)—, —OC(O)— and —OC(S)—;

each occurrence of m is independently 0 or 1; and

each occurrence of n is independently 1 or 2.

2. The compound of claim 1 , wherein X is O.

3. The compound of claim 1 , wherein R 3 is methyl.

4. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

A is 5- or 6-membered monocyclic heteroaryl, C 2 -C 6 alkynyl, —CH 2 NH 2 , —N(R 20 ) 2 , —S—(C 1 -C 6 alkyl), —S(O) 2 —(C 1 -C 6 alkyl), —NHC(O)N(R 20 ) 2 , —C(O)N(R 20 ) 2 , —NHC(O)R 20 or group A and the —OR 2 group of formula (I) can join to form —OC(O)—NH—;

B is:

R 1 is H or:

R 2 is H, or R 1 and R 2 join to form a group having the formula:

R 6 and R 11 are each independently —N(R 20 ) 2 ;

R 9 is —OH or —O—(C 1 -C 6 alkyl);

R 14 is C 6 -C 10 aryl;

R 15 and R 16 are each independently H or C 1 -C 6 alkyl;

R 17 and R 18 are each independently C 1 -C 6 alkyl; and

each occurrence of R 20 is independently H or —C(O)—(C 1 -C 6 alkyl).

5. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

A is 5- or 6-membered monocyclic heteroaryl, C 2 -C 6 alkynyl, —CH 2 NH 2 , —N(R 20 ) 2 , —S—(C 1 -C 6 alkyl), —S(O) 2 —(C 1 -C 6 alkyl), —NHC(O)N(R 20 ) 2 , —C(O)N(R 20 ) 2 , —NHC(O)R 20 or group A and the —OR 2 group of formula (I) can join to form —OC(O)—NH—;

B is:

R 1 is:

R 6 and R 10 are each independently —N(R 20 ) 2 ;

R 9 is —OH or —O—(C 1 -C 6 alkyl); and

each occurrence of R 20 is independently H or —C(O)—(C 1 -C 6 alkyl).

6. The compound of claim 1 , wherein A is —NH 2 .

7. The compound of claim 1 , wherein B is:

R 6 is —NH 2 or —NHC(O)CH 3 ; R 9 is —OH or —O—(C 1 -C 6 alkyl); and R 10 is —NH 2 .

8. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

A is C 2 -C 6 alkynyl or —NH 2 ;

B is:

R 1 is:

R 9 is —OH or —O—(C 1 -C 6 alkyl);

R 14 is phenyl, which can be optionally substituted with up to 2 halo groups, which can be the same or different; and

R 17 is C 1 -C 6 alkyl.

9. The compound of claim 1 , wherein R 14 is phenyl.

10. The compound of claim 1 , wherein R 17 is ethyl or isopropyl.

11. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

A is C 2 -C 6 alkynyl or —NH 2 ;

B is:

R 18 is aryl or C 1 -C 6 alkyl.

12. The compound of claim 11 , wherein R 18 is isopropyl.

13. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

B is:

R 1 is:

R 9 is —OH or —O—(C 1 -C 6 alkyl).

14. The compound of claim 1 , wherein B is

15. The compound of claim 1 , wherein B is

16. The compound of claim 1 , wherein B is

17. The compound of claim 1 , being any one of the compounds numbered 1-99 in the above specification, or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , having the structure:

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. The pharmaceutical composition according to claim 19 , further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

21. The pharmaceutical composition according to claim 20 , further comprising a third therapeutic agent selected from the group consisting of HCV protease inhibitors, HCV NS5A inhibitors and HCV NS5B polymerase inhibitors.

22. A method of treating a patient infected with HCV comprising the step of administering an amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, effective to treat infection by HCV in said patient.

23. The method according to claim 22 , further comprising the step of administering pegylated-interferon alpha and an HCV protease inhibitor to said patient.

24. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

25. The compound of claim 24 having the structure:

26. The compound of claim 24 having the structure:

27. The compound of claim 24 having the structure:

28. A pharmaceutically acceptable salt of the compound of claim 24 having the structure:

29. A pharmaceutically acceptable salt of the compound of claim 24 having the structure:

30. A pharmaceutically acceptable salt of the compound of claim 24 having the structure:

31. A pharmaceutical composition comprising (i) an amount of a compound of claim 25 , effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

32. A pharmaceutical composition comprising (i) an amount of a compound of claim 26 , effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising (i) an amount of a compound of claim 27 , effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising (i) an amount of the pharmaceutically acceptable salt of the compound of claim 28 , effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

35. A pharmaceutical composition comprising (i) an amount of the pharmaceutically acceptable salt of the compound of claim 29 , effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

36. A pharmaceutical composition comprising (i) an amount of the pharmaceutically acceptable salt of the compound of claim 30 , effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

37. A pharmaceutical composition comprising (i) a compound of claim 24 or a pharmaceutically acceptable salt thereof, and (ii) one or more additional therapeutic agents selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.

38. A method of treating a patient infected with HCV comprising the step of administering the compound of claim 25 , in an amount effective to treat infection by HCV in said patient.

39. A method of treating a patient infected with HCV comprising the step of administering the compound of claim 26 , in an amount effective to treat infection by HCV in said patient.

40. A method of treating a patient infected with HCV comprising the step of administering the compound of claim 27 , in an amount effective to treat infection by HCV in said patient.

41. A method of treating a patient infected with HCV comprising the step of administering a pharmaceutically acceptable salt of the compound of claim 28 , in an amount effective to treat infection by HCV in said patient.

42. A method of treating a patient infected with HCV comprising the step of administering a pharmaceutically acceptable salt of the compound of claim 29 , in an amount effective to treat infection by HCV in said patient.

43. A method of treating a patient infected with HCV comprising the step of administering a pharmaceutically acceptable salt of the compound of claim 30 , in an amount effective to treat infection by HCV in said patient.